WallStreetZenWallStreetZen

NASDAQ: DRTS
Alpha Tau Medical Ltd Stock Forecast, Predictions & Price Target

Analyst price target for DRTS

Based on 3 analysts offering 12 month price targets for Alpha Tau Medical Ltd.
Min Forecast
$7.00+164.15%
Avg Forecast
$8.00+201.89%
Max Forecast
$9.00+239.62%

Should I buy or sell DRTS stock?

Based on 3 analysts offering ratings for Alpha Tau Medical Ltd.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRTS stock forecasts and price targets.

DRTS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-22
lockedlocked$00.00+00.00%2024-03-08
lockedlocked$00.00+00.00%2023-12-15

1 of 1

Forecast return on equity

Is DRTS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
27.87%

Forecast return on assets

Is DRTS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

DRTS revenue forecast

What is DRTS's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$4.1M
Avg 2 year Forecast
$27.9M

DRTS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DRTS$2.65$8.00+201.89%Strong Buy
ATOS$1.46$6.00+310.96%Buy
ACHV$5.41$14.00+158.78%Strong Buy
VERU$1.27$4.00+214.96%Strong Buy
TELO$6.30N/AN/A

Alpha Tau Medical Stock Forecast FAQ

Is Alpha Tau Medical Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: DRTS) stock is to Strong Buy DRTS stock.

Out of 3 analysts, 2 (66.67%) are recommending DRTS as a Strong Buy, 1 (33.33%) are recommending DRTS as a Buy, 0 (0%) are recommending DRTS as a Hold, 0 (0%) are recommending DRTS as a Sell, and 0 (0%) are recommending DRTS as a Strong Sell.

If you're new to stock investing, here's how to buy Alpha Tau Medical stock.

What is DRTS's revenue growth forecast for 2026-2027?

(NASDAQ: DRTS) Alpha Tau Medical's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.15%.

Alpha Tau Medical's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast DRTS's revenue for 2026 to be $283,559,391, with the lowest DRTS revenue forecast at $283,559,391, and the highest DRTS revenue forecast at $283,559,391.

In 2027, DRTS is forecast to generate $1,941,023,250 in revenue, with the lowest revenue forecast at $1,941,023,250 and the highest revenue forecast at $1,941,023,250.

What is DRTS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: DRTS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is DRTS's Price Target?

According to 3 Wall Street analysts that have issued a 1 year DRTS price target, the average DRTS price target is $8.00, with the highest DRTS stock price forecast at $9.00 and the lowest DRTS stock price forecast at $7.00.

On average, Wall Street analysts predict that Alpha Tau Medical's share price could reach $8.00 by May 22, 2025. The average Alpha Tau Medical stock price prediction forecasts a potential upside of 201.89% from the current DRTS share price of $2.65.

What is DRTS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: DRTS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.